TABLE 4.

Median number of PBMC secreting IFN-γ (SFC/106) in response to influenza virus strains as measured at days 0, 6, and 13 by the ELISPOT assay

Strain, serostatus,a and treatmentDay 0bDay 6Day 13
ncMedian SFC/106 PBMC (95% CI)nMedian SFC/106 PBMC (95% CI)nMedian SFC/106 PBMC (95% CI)
A/H1N1
    All
        CAIV-T 10781 (1, 10)813 (1, 303)555 (37, 230)
        CAIV-T <105111 (1, 1)71 (1, 20)111 (1, 1)
        TIV91 (1, 3)101 (1, 122)93 (1, 17)
        Placebo81 (1, 2)81 (1, 23)91 (1, 13
    Seronegative
        CAIV-T 10761 (1, 3)68 (1, 303)555 (37. 230)
        CAIV-T <10591 (1, 1)61 (1, 1)101 (1, 1)
        TIV51 (1, 1)61 (1, 1)51 (1, 3)
        Placebo71 (1, 2)51 (1, 1)61 (1, 1)
A/H3N2
    All
        CAIV-T 10771 (1, 17)73 (1, 200)567 (23, 193)
        CAIV-T <105101 (1, 1)71 (1, 2)91 (1, 1)
        TIV91 (1, 3)81 (1, 85)63 (1, 124)
        Placebo71 (1, 1)71 (1, 1)61 (1, 10)
    Seronegative
        CAIV-T 10761 (1, 3)62 (1, 30)4104 (23, 193)
        CAIV-T <105101 (1, 1)71 (1, 2)81 (1, 1)
        TIV51 (1, 1)51 (1, 3)31 (1, 2)
        Placebo71 (1, 1)71 (1, 1)61 (1, 10)
B
    All
        CAIV-T 10771 (1, 2)63 (1, 33)5130 (1, 237)
        CAIV-T <10571 (1, 3)51 (1, 23)51 (1, 7)
        TIV51 (1, 10)51 (1, 3)51 (1, 63)
        Placebo51 (1, 13)41 (1, 1)51 (1, 15)
    Seronegative
        CAIV-T 10741 (1, 2)33 (1, 33)3213 (130, 237)
        CAIV-T <10531 (1, 1)11d31 (1, 1)
        TIV41 (1, 1)41 (1, 3)31 (1, 1)
        Placebo21 (1, 1)21 (1, 1)21 (1, 1)
  • a Subjects were defined as seronegative to a particular virus strain if their prevaccination HAI antibody titer to that strain was ≤1:4.

  • b Prevaccination.

  • c n, number of subjects in the calculation.

  • d The 95% CI could not be calculated.